NCT06356662RecruitingPhase 1
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 17 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 27 Mar 2024
- Start date
- 23 Jan 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Diseases
- Parkinson disease
- NCT number
- NCT06356662
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 60
- From 23 Jan 2024 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders
- 2: Or have received deep brain stimulation and other brain surgery
- 3: Abnormal liver and kidney function
- 4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)
- 5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence
- 6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor
- 7: Pregnant or lactating women and seniors over 65 years of age
- 8: Allergy or other contraindications to the investigational drug
Who the study is looking for
- 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guohua Zhao Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.